Williams Pete A

Ha Ahnul, Kim Young Kook, Lee Chang Kyu, Williams Pete A, Morgan James E, Shin Young In et al.

This study found oral nicotinamide improved retinal function (PhNR and B-wave) in normal-tension glaucoma patients, suggesting a potential neuroprotective role, but long-term studies are needed.

Mouhammad Zaynab A, Tribble James R, Nicol Alan, Andreopoulou Evgenia, García-Bermúdez Mariana Y, Aldana Blanca I et al.

Semaglutide protected retinal ganglion cells from degeneration in a glaucoma model by enhancing retinal glucose metabolism, suggesting a potential neuroprotective strategy for glaucoma via metabolic flexibility.

Kocherlakota Sai, Nicol Alan, Locri Filippo, Stebbins Karin J, Lorrain Daniel S, Tribble James R et al.

LPAR1 antagonist PIPE-791 failed to protect retinal ganglion cells, normalize vasculature, or reduce neuroinflammation in a rat ocular hypertension model. Reduced LPAR1 expression suggests targeting LPAR1 alone may not be a viable glaucoma neuroprotection strategy.

Vallbona-Garcia Antoni, Gustavsson Simon T, Gorgels Theo G M F, Tribble James R, Webers Carroll A B, Smeets Hubert J M et al.

Plasma eNAMPT levels didn't differ between glaucoma patients and controls, nor did supplementation change them. Thus, circulating eNAMPT isn't a direct glaucoma biomarker or short-term nicotinamide response indicator.

Hedström Johan, Nilsson Maria, Engvall Martin, Williams Pete A, Venkataraman Abinaya Priya

Manually correcting OCT segmentation of GCC in chronic LHON revealed strong correlations between GCC thickness and visual function, highlighting the need for accurate measurements to monitor disease and treatment effects.

Petriti Bledi, Rabiolo Alessandro, Chau Kai-Yin, Williams Pete A, Montesano Giovanni, Lascaratos Gerassimos et al.

This study found that lower immune cell (PBMC) oxygen consumption is strongly linked to faster vision loss in treated glaucoma patients, suggesting it's a new biomarker for progression.

Enz Tim J, Bittner Mario, Tribble James R, Williams Pete A, Thiel Michael A, Schmid Martin K et al.

This study found that brimonidine and brinzolamide eye drops, while lowering IOP, did not significantly alter retinal blood flow velocity in healthy adults, suggesting no detrimental ocular blood flow effects.

De Moraes Carlos Gustavo, John Simon W M, Williams Pete A, Blumberg Dana M, Cioffi George A, Liebmann Jeffrey M

This study found nicotinamide and pyruvate improved visual function in glaucoma patients, suggesting these supplements may offer neuroprotection and warrant further long-term investigation to slow progression.

Tribble James R, Otmani Amin, Kokkali Eirini, Lardner Emma, Morgan James E, Williams Pete A

This rat magnetic bead glaucoma model accurately mimics human RGC degeneration and vascular changes, making it a valuable platform for testing new glaucoma treatments.

Tribble James R, Kokkali Eirini, Otmani Amin, Plastino Flavia, Lardner Emma, Vohra Rupali et al.

Unilateral glaucoma models showed significant microglial activation in the contralateral "control" eye and visual pathways. This suggests caution when using the contralateral eye as a control in glaucoma research.

Hui Flora, Tang Jessica, Williams Pete A, McGuinness Myra B, Hadoux Xavier, Casson Robert J et al.

This study found nicotinamide supplementation improved inner retinal function (PhNR Vmax) in glaucoma patients, suggesting a potential adjunctive therapy to protect vision.

Casson Robert J, Chidlow Glyn, Crowston Jonathan G, Williams Pete A, Wood John P M

Glaucoma involves impaired retinal ganglion cell energy metabolism; bioenergetic therapies show promise for neuroprotection and visual recovery in humans.

Williams Pete A, Harder Jeffrey M, John Simon W M

This study found nicotinamide (vitamin B3) potently protected mouse eyes from glaucoma by boosting mitochondrial health, even with elevated eye pressure, suggesting a promising neuroprotective treatment for human glaucoma.

Williams Pete A, Harder Jeffrey M, Foxworth Nicole E, Cochran Kelly E, Philip Vivek M, Porciatti Vittorio et al.

Vitamin B3 prevented glaucoma in aged mice by boosting NAD+ and mitochondrial health, suggesting its potential as a therapeutic strategy for human glaucoma and other neurodegenerations.